{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:49:20Z","timestamp":1788274160771,"version":"build-2803163510"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,22]]},"DOI":"10.7759\/cureus.18983","type":"journal-article","created":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T21:23:36Z","timestamp":1634937816000},"source":"Crossref","is-referenced-by-count":4,"title":["Pembrolizumab-Induced Diabetic Ketoacidosis: A Review of Critical Care Case"],"prefix":"10.7759","author":[{"given":"Keerthana","family":"Sankar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Macfarlane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odelia","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Falk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang DY","year":"2018","unstructured":"Wang DY, Salem JE, Cohen JV, et al.. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018, 4:1721-8. 10.1001\/jamaoncol.2018.3923","journal-title":"JAMA Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.537","article-title":"Dissemination of information on potentially fatal adverse drug reactions for cancer drugs from 2000 to 2002: first results from the research on adverse drug events and reports project","volume":"21","author":"Ladewski LA","year":"2003","unstructured":"Ladewski LA, Belknap SM, Nebeker JR, et al.. Dissemination of information on potentially fatal adverse drug reactions for cancer drugs from 2000 to 2002: first results from the research on adverse drug events and reports project. J Clin Oncol. 2003, 21:3859-66. 10.1200\/JCO.2003.04.537","journal-title":"J Clin Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-50574-6","article-title":"Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab","volume":"9","author":"Eun Y","year":"2019","unstructured":"Eun Y, Kim IY, Sun JM, et al.. Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab. Sci Rep. 2019, 9:10.1038\/s41598-019-50574-6","journal-title":"Sci Rep"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k793","article-title":"Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis","volume":"360","author":"Baxi S","year":"2018","unstructured":"Baxi S, Yang A, Gennarelli RL, Khan N, Wang Z, Boyce L, Korenstein D. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. BMJ. 2018, 360:1-13. 10.1136\/bmj.k793","journal-title":"BMJ"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2016.1199310","article-title":"Pembrolizumab (Keytruda)","volume":"12","author":"Kwok G","year":"2016","unstructured":"Kwok G, Yau TC, Chiu JW, Tse E, Kwong YL. Pembrolizumab (Keytruda). Hum Vaccin Immunother. 2016, 12:2777-89. 10.1080\/21645515.2016.1199310","journal-title":"Hum Vaccin Immunother"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.14740\/wjon1085w","article-title":"Autoimmune diabetes associated with pembrolizumab: a review of published case reports","volume":"9","author":"Cheema A","year":"2018","unstructured":"Cheema A, Makadia B, Karwadia T, Bajwa R, Hossain M. Autoimmune diabetes associated with pembrolizumab: a review of published case reports. World J Oncol. 2018, 9:1-4. 10.14740\/wjon1085w","journal-title":"World J Oncol"},{"key":"ref7","unstructured":"Autoantibodies in type 1 diabetes. (2020). Accessed. December 1, 2020: http:\/\/www.hopkinsguides.com\/hopkins\/view\/Johns_Hopkins_Diabetes_Guide\/547013\/all\/Autoantibodies_in_Type_1_Diabetes."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of cancer immunotherapy targeting immune checkpoints","volume":"40","author":"Chang LS","year":"2019","unstructured":"Chang LS, Barroso-Sousa R, Tolaney SM, Hodi FS, Kaiser UB, Min L. Endocrine toxicity of cancer immunotherapy targeting immune checkpoints. Endocr Rev. 2019, 40:17-65. 10.1210\/er.2018-00006","journal-title":"Endocr Rev"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12024","article-title":"Report of the committee of the Japan Diabetes Society on the research of fulminant and acute-onset type 1 diabetes mellitus: new diagnostic criteria of fulminant type 1 diabetes mellitus (2012)","volume":"3","author":"Imagawa A","year":"2012","unstructured":"Imagawa A, Hanafusa T, Awata T, et al.. Report of the committee of the Japan Diabetes Society on the research of fulminant and acute-onset type 1 diabetes mellitus: new diagnostic criteria of fulminant type 1 diabetes mellitus (2012). J Diabetes Investig. 2012, 3:536-9. 10.1111\/jdi.12024","journal-title":"J Diabetes Investig"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(95)90645-2","article-title":"Diabetes ketoacidosis","volume":"345","author":"Lebovitz HE","year":"1995","unstructured":"Lebovitz HE. Diabetes ketoacidosis. Lancet. 1995, 345:767-72. 10.1016\/s0140-6736(95)90645-2","journal-title":"Lancet"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/74344-pembrolizumab-induced-diabetic-ketoacidosis-a-review-of-critical-care-case","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:32:06Z","timestamp":1707507126000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/74344-pembrolizumab-induced-diabetic-ketoacidosis-a-review-of-critical-care-case"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,22]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.18983","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10,22]]}}}